Morra, Simone http://orcid.org/0000-0001-5340-8569
Piccinelli, Mattia Luca
Cano Garcia, Cristina
Tappero, Stefano
Barletta, Francesco
Incesu, Reha-Baris
Scheipner, Lukas
Baudo, Andrea
Tian, Zhe
Saad, Fred
Mirone, Vincenzo
Califano, Gianluigi
Colla’ Ruvolo, Claudia
Shariat, Shahrokh F.
de Cobelli, Ottavio
Musi, Gennaro
Chun, Felix K. H.
Terrone, Carlo
Briganti, Alberto
Tilki, Derya
Ahyai, Sascha
Carmignani, Luca
Longo, Nicola
Karakiewicz, Pierre I.
Article History
Received: 19 June 2023
Accepted: 20 August 2023
First Online: 28 August 2023
Declarations
:
: Shahrokh F. Shariat: Horonraria: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen. Consulting or Advisory Role: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen. Speakers’ Bureau: Astellas, Astra Zeneca, Bayer, BMS, Cepheid, Ferring, lpsen, Janssen, Lilly, MSD, Olympus, Pfizer, Pierre Fabre, Richard Wolf, Roche, Sanochemia, Sanofi, Takeda, Urogen, Movember Foundation. Patents: Method to determine prognosis after therapy for prostate cancer - granted 2002-09-06, Methods to determine prognosis after therapy for bladder cancer - granted 2003-06-19, Prognostic methods for patients with prostatic disease - granted 2004-08-05; Soluble Fas urinary marker for the detection of bladder transitional cell carcinoma - granted 2010-07-20. Our research was conducted without any other potential conflicts of interest.
: All analyses and their reporting followed the SEER reporting guidelines. Due to the anonymously coded design of the SEER database, study‐ specific Institutional Review Board ethics approval as not required.